Liquid biopsy: monitoring cancer-genetics in the blood

  title={Liquid biopsy: monitoring cancer-genetics in the blood},
  author={Emily Crowley and Federica Di Nicolantonio and Fotios Loupakis and Alberto Bardelli},
  journal={Nature Reviews Clinical Oncology},
Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations is increasingly used for diagnostic, prognostic and treatment purposes. The genetic profile of solid tumours is currently obtained from surgical or biopsy specimens; however, the latter procedure cannot always be performed routinely owing to its invasive nature. Information acquired from a single biopsy provides a spatially and temporally limited snap-shot of a tumour and might fail to reflect its… 

Figures and Tables from this paper

Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA.
  • T. Yoo
  • Biology, Medicine
    Advances in experimental medicine and biology
  • 2021
This chapter will explore how tumor cells and tumor-associated mutations detected in the blood can be used in the clinic, including detection of cancer, prediction of prognosis, monitoring systemic therapies, and stratification of patients for therapeutic targets or resistance mechanisms.
This communication will explore how LB is associated with personalized oncology to predict response to treatments and the development of acquired resistance.
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers
The implementation and standardization of both approaches are still needed to achieve the required sensitivity and specificity to successfully analyze heterogenous tumours, but pivotal studies have shown the feasibility and usefulness of liquid biopsy for monitoring the Darwinian clonal evolution from an early to a metastatic stage.
Liquid biopsies: advancing cancer research through drops of blood
  • A. Khattak
  • Medicine, Biology
    Internal medicine journal
  • 2016
Serial liquid biopsies can be performed to give a better understanding of the evolution of tumour with time, identify various prognostic and predictive biomarkers and identify mechanism of resistance to targeted therapy.
Circulating tumor cells: Screening and monitoring of oral cancers.
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
  • Meng Yang, M. Forbes, Wei Zhang
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2018
The futuristic concept of TNMB tumor classification is put forward, opening a new horizon for precision medicine with the hope of creating better outcomes for cancer patients.
Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing
Targeted therapy specifically aims at tumor genetic alterations is the hallmark of precision medicine. Companion diagnostic testing utilized to determine the presence or absence of certain oncogenic


Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Serial analysis of cancer genomes in plasma constitutes a new paradigm for the study of clonal evolution in human cancers, establishing proof of principle that exome-wide analysis of circulating tumour DNA could complement current invasive biopsy approaches to identify mutations associated with acquired drug resistance in advanced cancers.
Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers
Tumor genomic instability and selective treatment pressures result in clonal disease evolution; molecular stratification for molecularly targeted drug administration requires repeated access to tumor
Circulating mutant DNA to assess tumor dynamics
It is found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy, and it is suggested that this personalized genetic approach could be generally applied to individuals with other types of cancer.
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
The genomic landscape of prostate cancer can be established by non-invasive means from plasma DNA by developing an approach based on a benchtop high-throughput platform, that is, Illuminas MiSeq instrument.
Circulating tumour markers can define patients with normal colons, benign polyps and cancers
The best three marker DNA model was able to discriminate the normal population from populations with adenoma and carcinoma with a ROC curve of 0.810, which offers the prospect of a simple blood test to screen for colorectal cancers and polyps.
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.
The potential of SNP/CNV analysis of cfDNA to distinguish between patients with breast cancer and healthy controls during routine follow-up is demonstrated, and specific CNVs were detected in cfDNA, mirroring the primary tumor, up to 12 yr after diagnosis despite no other evidence of disease.
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Levels of mutant alleles reflected the clinical course of the disease and its treatment—for example, stabilized disease was associated with low allelic frequency, whereas patients at relapse exhibited a rise in frequency, and TAm-Seq will need to achieve a more sensitive detection limit to identify mutations in the plasma of patients with less advanced cancers.
Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma
The results suggest that the assessment of microsatellite status in the serum DNA could be a useful predictive tool to monitor disease prognosis.
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
An approach to directly identify tumor-derived chromosomal alterations through analysis of circulating cell-free DNA from cancer patients is described and represents a useful method for the noninvasive detection of human tumors that is not dependent on the availability of tumor biopsies.
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.
This study explored the use of shotgun massively parallel sequencing of plasma DNA from cancer patients to scan a cancer genome noninvasively and showed that plasma DNA sequencing is a valuable approach for studying tumoral heterogeneity.